Lumos Pharma Inc   (LUMO)
Other Ticker:  
Price: $1.4600 $0.01 0.690%
Day's High: $1.54 Week Perf: -2.67 %
Day's Low: $ 1.46 30 Day Perf: -33.64 %
Volume (M): 9 52 Wk High: $ 4.55
Volume (M$): $ 14 52 Wk Avg: $2.94
Open: $1.48 52 Wk Low: $1.37

 Market Capitalization (Millions $) 12
 Shares Outstanding (Millions) 8
 Employees -
 Revenues (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) -37
 Cash Flow (TTM) (Millions $) -21
 Capital Exp. (TTM) (Millions $) 0

Lumos Pharma Inc
Lumos Pharma Inc is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of therapeutics for rare diseases. The company primarily targets disorders with serious unmet medical needs and limited treatment options. They aim to bring innovative and effective treatments to patients suffering from these rare diseases. Lumos Pharma's pipeline includes candidates for diseases like Creatine Transporter Deficiency, Pediatric Growth Hormone Deficiency, and Mucopolysaccharidosis Type III. Their mission is to improve patients' quality of life and become a leading player in the rare disease therapeutics market.

   Company Address: 4200 Marathon Blvd #200 Austin 78756 TX
   Company Phone Number: 215-2630   Stock Exchange / Ticker: NASDAQ LUMO


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Stocks on the Move

Advancements in Rare Disease Therapeutics BridgeBio Pharma and Lumos Pharma Lead the Way

Published Fri, Jul 12 2024 6:28 PM UTC

The biopharmaceutical industry has witnessed significant developments in recent times with companies like BridgeBio Pharma and Lumos Pharma making significant breakthroughs in rare disease therapeutics. This article will provide an overview of the recent advancements by these companies, along with their financial performance and market trends.BridgeBio Pharma Reveals Promisi...

Clinical Study

Lumos Pharma Unveils New Insights from Phase 2 OraGrowtH212 Trial at ENDO 2024

Published Tue, Jun 4 2024 1:01 PM UTC

Lumos Pharma, a clinical-stage biopharmaceutical company specializing in rare disease therapeutics, has revealed fresh analyses of data from its Phase 2 OraGrowtH212 clinical trial. The findings were presented at the 2024 Annual Meeting of the Endocrine Society (ENDO) held in Boston from June 1-4, 2024. This article examines the key details and implications of Lumos Pharma's...

Product Service News

Lumos Pharma's Phase 2 Clinical Trial Data Accepted for Presentation at ENDO 2024 Conference

Published Mon, May 20 2024 8:05 PM UTC

Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024Lumos Pharma, a clinical stage biopharmaceutical company dedicated to developing therapeutics for rare diseases, has recently announced that new data analyses from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted for presentation in two posters at the 2024 Annual Meeting of the...

Lumos Pharma Inc

2. Groundbreaking Developments and Patent Protection Propel Lumos Pharma Inc Forward

Lumos Pharma Inc's recent financial report may have been disappointing, but there is still reason for optimism in the biopharmaceutical company's future. Despite a significant decline in revenue and an increased shortfall per share compared to the previous year, Lumos Pharma has announced some groundbreaking developments that have the potential to propel the company forward.
In a major milestone, Lumos Pharma has been granted patent protection by the United States Patent and Trade Office (USPTO) for its novel formulation of LUM-201. This patent extends Lumos Pharma's exclusivity period until 2042, opening up new possibilities for the treatment of Pediatric Growth Hormone Deficiency (PGHD). This is a significant achievement for the company, as it recognizes the improved formulations of LUM-201 outlined in the patent application, which aim to enhance efficacy, improve patient compliance, and optimize treatment outcomes for children suffering from PGHD.

Product Service News

Lumos Pharma Secures Patent Protection for Novel Formulation of LUM-201, Paving the Way for Extended Exclusivity in Pediatric Growth Hormone Deficiency Treatment

Published Wed, Mar 20 2024 12:00 PM UTC

In a groundbreaking development, Lumos Pharma, a leading biopharmaceutical company focused on pediatric healthcare, has announced the grant of patent protection by the United States Patent and Trade Office (USPTO) for its novel formulation of LUM-201. This significant milestone extends Lumos Pharma's exclusivity period until 2042 and unlocks new possibilities for the treatme...


Lumos Pharma Inc's Segments
• View Complete Report
  Company Estimates  
  Revenue Outlook
Lumos Pharma Inc does not provide revenue guidance.

Earnings Outlook
Lumos Pharma Inc does not provide earnings estimates.

Geographic Revenue Dispersion


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com